Lim, Emerson A.
Columbia University Irving Medical Center
3 papers on CoChatORCID 0000-0001-7269-349X
Most cited papers
- Verified
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 62
- Verified
Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., et al. (2021) · Cancer Discovery
Computational Drug Discovery MethodsCancer Genomics and Diagnostics
Cited by 51
- Verified
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).
Vaena, D. A., Fleming, G. F., Chmielowski, B., Sharma, M., Hamilton, E. P., Sullivan, R. J., Shepard, D. R., Papadopoulos, K. P., Patnaik, A., ElNaggar, A., et al. (2021) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free